Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

D-Pharm Ltd.

www.dpharm.com

Latest From D-Pharm Ltd.

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

Deals M & A

New Fosun Funds to Support Gland Bid, Growth, Lower Debt

Hong Kong-listed Fosun Pharmaceutical plans to use new funds raised from super short-term commercial papers to back its subsidiary Jiangsu Wangban Pharmaceutical, and to add liquidity to its non-binding proposal to acquire Indian firm Gland. The group also says it has clear plans to reduce debts to obtain a higher investment rating.

BioPharmaceutical Asia Pacific

Stockwatch: Which way is up?

As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (scripintelligence.com, 25 October 2012).

Cancer

Neuroprotection in stroke: worth another crack?

Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise for a protein acting on a post-synaptic brain protein. Together with some promising early data for two other potential neuroprotective agents, experts say the data seem to support renewed efforts in developing such drugs despite their chequered developmental history.

Cardiovascular Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • D-Pharm Ltd.
  • Senior Management
  • Alex Kozak, PhD, Pres. & CEO
    Gilad Rosenberg, MD, VP, Clin. Dev.
    Ofra Yamin, VP, Fin. & Human Resources
  • Contact Info
  • D-Pharm Ltd.
    Phone: (972) 8-9385100
    Kiryat Weizmann Sci. Park
    Bldg. 7
    P.O. Box 2313 Rehovot, 76123
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register